Canalis Ernesto
Department of Research, Saint Francis Hospital and Medical Center, Hartford, and University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Curr Opin Rheumatol. 2003 Jul;15(4):454-7. doi: 10.1097/00002281-200307000-00013.
Glucocorticoids modify osteoblastic cell differentiation, number, and function. Glucocorticoids stimulate osteoclastogenesis and increase the expression of receptor activator of Nuclear factor-kappaB ligand and colony-stimulating factor-1, and decrease the expression of osteoprotegerin. However, the most significant effect of glucocorticoids in bone is an inhibition of bone formation. This inhibition is caused by a decrease in the number of osteoblasts secondary to a shift in the differentiation of mesenchymal cells away from the osteoblastic lineage, and an increase in the death of mature osteoblasts. Glucocorticoids decrease the function of the remaining osteoblasts directly and indirectly through the inhibition of insulin-like growth factor I expression. The stimulation of bone resorption is likely responsible for the initial bone loss after glucocorticoid exposure. Eventually, the inhibition of bone formation will cause a decrease in bone remodeling and a continued increased risk of fractures.
糖皮质激素可改变成骨细胞的分化、数量及功能。糖皮质激素刺激破骨细胞生成,增加核因子κB受体活化因子配体及集落刺激因子-1的表达,并降低骨保护素的表达。然而,糖皮质激素对骨骼最显著的影响是抑制骨形成。这种抑制是由于间充质细胞分化从成骨细胞谱系转变导致成骨细胞数量减少,以及成熟成骨细胞死亡增加所致。糖皮质激素通过抑制胰岛素样生长因子I的表达直接和间接降低剩余成骨细胞的功能。骨吸收的刺激可能是糖皮质激素暴露后初期骨质流失的原因。最终,骨形成的抑制将导致骨重塑减少,骨折风险持续增加。